Mining the microbiota for microbial and metabolite-based immunotherapies

Ashwin N. Skelly, Yuko Sato, Sean Kearney, Kenya Honda

研究成果: Review article査読

188 被引用数 (Scopus)

抄録

Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.

本文言語English
ページ(範囲)305-323
ページ数19
ジャーナルNature Reviews Immunology
19
5
DOI
出版ステータスPublished - 2019 5月 1

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「Mining the microbiota for microbial and metabolite-based immunotherapies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル